

Table of Contents

1. Questions
2. Summary of five GME Studies on the removal and inactivation of potential TSE infectivity by the different bone gelatine manufacturing processes
3. Summaries of previous relevant Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) meetings:
 - TSEAC Meeting, April 23 & 24, 1997 (1 page)
 - TSEAC Meeting, April 15 & 16, 1998 (5 pages)
 - Joint Meeting of the Transmissible Spongiform Encephalopathies Advisory Committee And Vaccines and Related Biological Products Advisory Committee, July 27, 2000 (2 pages)
Web address: <http://www.fda.gov/cber/advisory/tse/tseum072700.htm>
 - TSEAC Meeting, June 28 & 29, 2001 (6 pages) – Refer to Topic #3
Web address: <http://www.fda.gov/ohrms/dockets/ac/01/minutes/3762m1.pdf>
 - TSEAC Meeting, October 25 & 26, 2001 (5 pages) – Refer to Topic #3
Web address: <http://www.fda.gov/ohrms/dockets/ac/01/minutes/3796m1.doc>
4. FDA Guidance “The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use.” (16 pages)
Web address: <http://www.fda.gov/opacom/morechoices/industry/guidance/gelguide.htm>
5. EMEA Explanatory Note “Gelatin for use in pharmaceuticals: Explanatory Note (13 December 2000) on the manufacture of gelatin in relationship to the CPMP Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products (CPMP/BWP/1230/98 rev 1)”. (1 page)
Web address: <http://www.emea.eu.int/pdfs/human/press/pus/430600en.pdf>
6. EMEA – “Note for Guidance on Minimising Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products”. (EMEA/410/01 rev.1, May 31, 2001) (12 pages).
Web address: <http://www.emea.eu.int/pdfs/vet/regaffair/041001en.pdf>

7. EC Directive No 999/2001 TSE Regulation as regards monitoring of bovine spongiform encephalopathy, eradication of transmissible spongiform encephalopathy, removal of specified risk materials and rules for importation of live animals and products of animal origin. (40 pages)

Web address: http://europa.eu.int/comm/food/fs/bse/bse36_en.pdf

8. Commission Regulation (EC) No 1494/2002 amending Annexes III, VII and XI to Regulation (EC) No 999/2001 of the European Parliament and the Council as regards monitoring of bovine spongiform encephalopathy, eradication of transmissible spongiform encephalopathy, removal of specified risk materials and rules for importation of live animals and products of animal origin (Text with EEA relevance).^{*} (8 pages)

^{*}Note that the amendment makes the following change (in **bold**), among other changes not relevant to this discussion, to Annex XI, Section 1(a)(i):

- (a) The following tissues are designated as specified risk material:

the skull including the brain and eyes, the tonsils, **the vertebral column excluding the vertebrae of the tail, the transverse processes of the lumbar and thoracic vertebrae and the wings of the sacrum, but including dorsal root ganglia**, and spinal cord of bovine animals aged over 12 months, and the intestines from the duodenum to the rectum and the mesentery of bovine animals of all ages;

Web address: http://europa.eu.int/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=EN&numdoc=32002R1494&model=guichett